Chemotherapy-induced neuropathy (CIN), which often results from a number of commonly used oncologic drugs, including taxanes, platinum agents, bortezomib, vinca alkaloids, ixabepilone, and eribulin, is one of the most debilitating symptoms caused by chemotherapy. Most research on this toxicity has focused on paclitaxel and oxaliplatin, both of which are used frequently and can cause severe neurotoxicity.
in subsequent cycles. Although acute CIN commonly peaks at 3 days and then starts to improve, these symptoms persist to a lesser degree between 2-week oxaliplatin repeat doses. 5 Substantial data illustrate that the degree of acute oxaliplatin neuropathy in individual patients predicts the degree of the more bothersome and persistent CIPN. 5 Paclitaxel has long been known to cause an acute pain syndrome classically characterized as arthralgias or myalgias. However, newer data support classification of the paclitaxel-associated acute pain syndrome (P-APS) as a manifestation of acute neuropathy rather than true joint or muscle pathology. 2, 3, 6 Although symptom severity also peaks at about 3 days after a dose of paclitaxel, the acute neuropathy symptoms of paclitaxel differ from those of oxaliplatin. The predominant complaint is pain, usually in a trunk/upper leg/hip distribution. As with oxaliplatin, the severity of acute neuropathy symptoms in the first cycle correlates with the severity of symptoms in subsequent cycles. 2, 3 However, as is not the case with oxaliplatin, the severity of acute neuropathy symptoms does not worsen with subsequent treatment cycles. 2, 3 Some data support the severity of P-APS as a predictor of severity of chronic paclitaxel neuropathy (CIPN), but not to the extent of oxaliplatin. caused by a specific mutation in one of the more than 50 different "CMT genes," are predisposed to develop severe CIPN when exposed to vincristine [7] [8] [9] [10] and occasionally have been diagnosed with CMT only after initiation of chemotherapy. [9] [10] [11] [12] [13] [14] [15] CMT is thus a contraindication to neurotoxic chemotherapy. However, CMT is a rare condition, leaving the majority of CIPN cases unexplained. Moderately strong evidence exists at least partially relating these cases to other genetic variants that are not otherwise disease-causing and that were identified by genome-wide association studies 16, 17 or, more recently, by next-generation genome sequencing. 18 The effect size of each of these genetic variants appears comparably small, with none currently being clinically actionable.
Recognizing the magnitude of the problem posed by CIPN, extensive efforts have been directed at prevention. Recent American Society of Clinical Oncology (ASCO) guidelines identified 42 randomized controlled trials that investigated agents previously hypothesized to protect against CIPN. Unfortunately, the composite data were unable to establish value
for any of the agents tested in these clinical trials, making it imperative that oncology providers closely evaluate patients who receive neurotoxic chemotherapy agents. If a patient develops a moderate or worse neuropathy, it is appropriate to reassess the potential benefits of the offending chemotherapy agent in view of the ongoing toxicity.
Despite efforts to be cognizant of CIPN and to stop chemotherapy in response to worsening symptoms, many patients are left with substantial neuropathy for months to years after cessation of treatment. Recent ASCO guidelines evaluated treatment approaches for established CIPN, identifying six published randomized, controlled trials. 19 The one positive recommendation from the ASCO Guideline Committee was for the use of duloxetine, a drug that has proved more effective than placebo in patients who had substantial neuropathic pain after treatment with paclitaxel or oxaliplatin. 20 However, the magnitude of benefit was quite limited. Subset analyses suggested that duloxetine worked better for neuropathy associated with oxaliplatin than with paclitaxel. An abstract of a subsequent trial, presented after the ASCO guidelines were published, provides additional confirmation that duloxetine decreases CIPN. 21 In addition to duloxetine, the ASCO guidelines noted three other classes of medications reasonable to try in clinical practice despite no definitive evidence for their efficacy. One of these is the gabapentinoid class (e.g., gabapentin or pregabalin), which has been found to be beneficial for patients having other types of neuropathies. This recommendation was made even though the one placebo-controlled trial of gabapentin for CIPN was convincingly negative. 22 More data are needed regarding the utility of gabapentinoids in this setting. Tricyclic antidepressants (TCAs) were also considered to be reasonable to try for CIPN based on their utility in other neuropathy states, even though only two small trials have looked at such drugs in patients with symptomatic CIPN, each failing to show any substantial improvement in symptoms. 23, 24 Last, a topical preparation of baclofen, amitriptyline, and ketamine was presented as a potential option based on results of one placebo-controlled trial that provided evidence suggestive of benefit. New research approaches are certainly needed to prevent or treat CIN.
Improved ability to identify who will be at risk for severe neuropathy from a given chemotherapy drug would help tailor oncologic regimens and initiate early symptom management to optimize quality of life. n Chemotherapy-induced Neuropathy-Where Are We Now?
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